Semax / Selank Blend
Status
Approved elsewhere. No FDA-approved labeling exists for either component or the combination. Both are registered medicines in Russia and neither is approved in the United States or the European Union.
What it is
A nasal blend pairing two Russian research peptides.
What published research measured
Pairs two peptides developed at the same Russian institute, one derived from ACTH fragment 4-10 and directed at cognition and neuroprotection, the other a tuftsin derivative directed at anxiety. Both are registered medicines in Russia and both share the same evidence limitation: trials come almost entirely from the originating research tradition, are largely published in Russian, are small, and have not been independently replicated or registered internationally. No blend in this category has been studied as a blend. Trial evidence, where it exists, was generated on single agents given alone; no published study of the combination for interaction, additive adverse effects or altered pharmacokinetics was identified in the sources reviewed for this entry. Two practical consequences follow. A multi-compound vial is a compounded preparation, so the stability of each component in the presence of the others, and over the life of the vial, is generally unstudied. If a reaction occurs, multiple components make it difficult to attribute it to one of them, which is one reason clinical pharmacology usually introduces agents one at a time.
Source
Not tied to a single designated source; see the published research on this molecule
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.